Rare Daily Staff

Rare disease drug company Retrophin said its CEO Stephen Aselage will retire and that the company’s board of directors has initiated a global search for his successor that will include both internal and external candidates.

Aselage will remain in his role as CEO until his replacement is appointed.

The company also announced that it named Noah Rosenberg as its chief medical officer. He will be responsible for overseeing the clinical development of Retrophin’s product pipeline. Rosenberg brings to Retrophin more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization.

He joins Retrophin from Medimetriks Pharmaceuticals, where he served as chief medical officer. Prior to that, he served as chief medical officer of Esperion Therapeutics, served as the executive director and head of cardiovascular and metabolism clinical development for the Forest Research Institute, and held leadership roles in clinical development, medical affairs and administration at Sanofi Aventis and Pfizer.

He completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai, holds an M.D. from the Drexel University College of Medicine, and received his B.A. from Johns Hopkins University.

Separately, Alberio Pharma, which is developing therapies for rare pediatric liver diseases, said it appointed Patrick Horn as chief medical officer. Horn will succeed Paresh Soni, who will step down from the chief medical officer, but will continue as a consultant to the company.

Horn is a pediatrician with development experience in both large pharmaceutical and biotech companies, including two orphan disease companies. Most recently, he was senior vice president, medical and clinical development at Orphan Technologies, where he was responsible for the development of treatments for homocystinuria.

Prior to that, he was chief medical officer at Tetraphase Pharmaceuticals and led the clinical program at Dyax Corp. He began his career in industry at Abbott Laboratories, culminating in his role as the head of clinical pharmacology.

Before working in industry, Horn was a practicing pediatrician in Chicago for almost 20 years and served as an associate professor of clinical pediatrics at the University of Chicago. He received both his M.D. and Ph.D. in Pharmacology from the University of Chicago and completed a pediatric residency at Boston Children’s Hospital.

July 31, 2018
Photo:
Stephen Aselage, CEO of Retrophin